Section 4 of 6
Clinical evidence
234 evidence topics · 25 sources
Study summaries
Triac trial I
Objective
Stated aim of the trial
“We therefore aimed to evaluate the effectiveness and safety of Triac treatment for peripheral thyrotoxicosis in paediatric and adult patients with MCT8 deficiency. In view of the wide spectrum of patient age in our study, neurocognitive changes were assessed in an exploratory way only.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Study hypothesis
“Therefore, we hypothesised that Triac treatment could effectively reduce serum T3 concentrations, thereby improving the negative clinical sequelae of chronic tissue thyrotoxicosis in patients with MCT8 deficiency. Triac might also offer beneficial effects on neurodevelopment if treatment is commenced early in life.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Study sites
“We enrolled patients at 11 sites (ten hospitals and one outpatient facility) in eight countries in Europe (Belgium, Czech Republic, France, Germany, Italy, the Netherlands, Romania, and the UK) and one site in South Africa (appendix p 3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Study design
Investigator-initiated, open-label, single-arm, phase 2 design
“In this investigator-initiated, multicentre, open-label, single-arm, phase 2, pragmatic trial, we investigated the effectiveness and safety of Triac in male patients with MCT8 deficiency.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All patients were assigned to receive Triac for 12 months. The trial was originally intended to be a national study in the Netherlands, but it was amended to allow additional enrolment of patients in other countries.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“An independent data safety monitoring board monitored patient safety.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment extension period
“To ascertain long-term effectiveness and safety, the patients enrolled in the Netherlands could enter an open-label treatment extension period, the endpoint of which was defined as the completion date of the last patient in other countries.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Inclusion criteria
“Patients with MCT8 deficiency (confirmed by the presence of a mutation in the SLC16A2 gene) were eligible to participate, irrespective of their age and comorbidities. Patients were either known to the investigators through direct care or were enrolled in the trial after their doctors or parents became aware of the trial through its ClinicalTrials.gov registration.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion criteria
“Exclusion criteria were major illness or major surgery within the past 4 weeks, enrolment in other randomised controlled trials, allergy to components in Triac tablets, and the presence of any contraindications to Triac treatment (appendix p 13).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Withdrawal criteria
“Patients could be withdrawn from the trial at the request of the parents or guardians, if continued participation was considered to be harmful to participants’ health by the investigators because of dose-limiting toxicities, or because of non-adherence to the trial protocol, premature termination of the trial, or loss to follow-up (appendix p 13).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
German benefit assessment: eligible sex, age, and genotype
Treatment
Washout of prior thyroid medication
“All participants discontinued treatment with antithyroid drugs, levothyroxine, or both (if applicable) before commencing treatment with the study drug. After a washout period of at least 4 weeks, baseline measurements were recorded.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Dose-escalation protocol and serum total T3 target
“We treated all patients with Triac (Téatrois tablets [350 µg], taken orally; Rare Thyroid Therapeutics, Stockholm, Sweden) with individualised dose-escalation that followed a predefined dose-escalation protocol: after the initial dose of 350 µg Triac (one tablet) once per day was given and no predefined dose-limiting toxic effects were identified, the daily dose was increased progressively in 350 µg increments (one tablet) with no maximum dose defined, with a goal of attaining serum total T3 concentrations within the target range of 1·4–2·5 nmol/L.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The maintenance Triac dose was continued for the rest of the study period (appendix p 4), but it could be further adjusted according to the dose-escalation protocol if T3 concentrations were outside the target range during control visits (appendix p 4).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Dose required to reach the target range
“The median time to achieve serum T3 concentrations within the target range was 2·5 months (IQR 1·5–3·7), which required a mean daily Triac dose of 38·3 µg/kg of bodyweight (SD 15·3; range 6·4–84·3), administered as a median of three doses per day (IQR 2–3; appendix p 6).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median daily Triac dose remained stable after the dose-escalation phase, although seven (16%) of 45 patients required further dose adjustments to maintain T3 concentrations within the target range (appendix p 6). The median daily Triac dose during the final study visit, either at month 12 or at time of withdrawal, was 37·0 µg/kg bodyweight (IQR 28·9–47·2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prescribing information: Study 2 dose titration and maintenance dose
Study outcomes
Rationale for using serum t3 concentration as the primary endpoint
Primary and co-primary endpoints
“The prespecified main primary endpoint was the change in the serum T3 concentrations between baseline and month 12. The prespecified co-primary endpoints were the change in serum TSH, free and total T4, and total reverse T3 concentrations between baseline and month 12.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Rationale stated by the investigators: chronic tissue thyrotoxicosis
“The endocrine hallmark of MCT8 deficiency is increased serum T3 concentrations, reduced free T4, and normal thyroid-stimulating hormone (TSH) concentrations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This chronic tissue thyrotoxicosis in patients with MCT8 deficiency leads to tachycardia, muscle wasting, hypermetabolism, and progressive reduction in bodyweight for age, causing substantial morbidity and mortality” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Secondary endpoints
“The prespecified secondary endpoints were the change between baseline and month 12 in bodyweight (expressed as bodyweight-for-age Z score, to account for natural development in children); mean heart rate, measured by 24 h ambulatory cardiac monitoring, and resting heart rate, measured by electrocardiography, both in bpm; blood pressure (in mm Hg and percentiles, based on reference ranges in healthy people;” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“mean of two measurements); and established biochemical parameters that reflect thyroid hormone activity in the liver (sex hormone-binding globulin and total cholesterol) and muscle (creatine kinase). Bodyweight was assessed instead of BMI, because accurate height measurements can be hampered by scoliosis and contractures.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Safety assessments, post-hoc endpoints, and endpoints not reported
“The prespecified assessments were the documentation of adverse events; echocardiography and 24-h monitoring of heart rhythm; bone mineral density measurement; and biochemical evaluations, including renal and liver function tests and bone turnover markers (appendix).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Post hoc, we also assessed the change in all available primary and secondary endpoints between baseline and the end of the treatment extension period in the participants treated for this time.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although the measurement of energy expenditure (secondary endpoint) and hair cortisol concentrations (exploratory endpoint) were prespecified endpoints, their acquisition was compromised by technical difficulties and are, therefore, not reported.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size calculation
“We did a power calculation based on a one-sample t test to estimate the difference in serum T3 concentrations after 12 months of treatment, by use of a mean serum T3 concentration of 4·3 nmol/L (SD 1·2), which we derived from a historical group of 31 patients with MCT8 deficiency (unpublished data). With ten patients we would have 80% power (at a significance level of 0·05) to detect a mean decrease in serum T3 concentrations from 4·3 nmol/L to 3·3 nmol/L.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After approval by all relevant ethical committees, we recruited additional patients to ascertain uniform documentation of the effects of Triac in this rare disorder and to provide more meaningful data on secondary outcomes and safety measures.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Screened, enrolled, and analyzed populations
| Population | Participants |
|---|---|
| Screened and eligible | “50”View highlighted excerpt for this quote |
| Declined participation | “four (8%)”View highlighted excerpt for this quote |
| Enrolled | “46 (92%)”View highlighted excerpt for this quote |
| Primary endpoint analysis | “45 (98%)”View highlighted excerpt for this quote |
| Completed the 12-month intervention period; secondary and exploratory endpoint analyses | “40 (87%)”View highlighted excerpt for this quote |
| Treatment extension period | “Ten (22%)”View highlighted excerpt for this quote |
Description of analysis sets
Full analysis set, completer set, and safety population
“Analyses of the prespecified primary endpoints were based on the full analysis dataset, which included all patients who received at least one dose of Triac and who had at least one control visit after the baseline assessment (appendix p 4). As such, patients who withdrew were included in the analyses, with their last available measurement used. The main analyses of the prespecified secondary endpoints were done in all patients who completed 12 months of treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Analyses of safety endpoints were done in the safety population, which included all patients exposed to at least one dose of the study drug.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Statistical methods
“For all prespecified primary and secondary endpoints, p values and 95% CIs were calculated for the mean change between baseline and month 12 by use of paired Student’s t tests. Serum TSH and creatine kinase concentrations were first log-transformed to normalise the distribution. For all prespecified exploratory and safety measures, 95% CIs were calculated for the mean change between baseline and 12 months of Triac treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Two-sided p values of less than 0·05 were considered to denote statistical significance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“CIs for exploratory measures have not been adjusted for multiplicity and these data should not be used to infer definitive treatment effects.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Missing data
“With the assumption that omission of data occurred randomly, and given the broad age range of the participants and small group size, pairwise deletion was used to adjust for missing data that were only captured at baseline and 12 months; for missing data that were captured throughout the study, the last available measurement was used.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“If 12-month measurements were not available, the last available observation in the same patient was used (<3% of included datapoints).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver-reported outcomes: post-hoc analysis methods
Results
Participant disposition
Enrollment and withdrawals
“Between Oct 15, 2014, and June 1, 2017, we screened 50 patients, all of whom were eligible. Of these patients, four (8%) patients decided not to participate because of travel commitments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of these 50 patients, four declined to participate; 46 patients were therefore enrolled and assigned to receive Triac (appendix p 5), but one (2%) patient was withdrawn before the first control visit because of non-compliance to study procedures. This patient was included in safety analyses, but not primary efficacy analyses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Five of these patients did not complete the study intervention: two were withdrawn due to parental choice (one because of travel time to the study centre, one because of severe comorbidity [severe epileptic seizures and hydrocephalus]), one was lost to follow-up, one developed Graves’ disease, and one patient died from sepsis. 40 (87%) patients completed the 12-month intervention period and thus were included in the analyses of secondary and exploratory endpoints. Ten (22%) patients who completed the follow-up were also included in the long-term (median 40·4 months, IQR 38·1–41·3) treatment extension period (appendix p 5).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Age, serum T3, bodyweight, and developmental status at baseline
“At baseline, the median age of the overall study population (n=46) was 7·1 years (range 0·8–66·8) and the mean serum T3 concentration was 4·91 nmol/L (SD 1·57), which was more than 1·6-times the upper limit of the normal range for age (table 1). The mean weight-for-age Z score was –2·84 (1·88) and 30 (65%) of the 46 enrolled patients were underweight (Z score less than –2). All patients had severe intellectual and motor disability: 41 (89%) of 46 patients were wheelchair-bound and had not reached early developmental milestones such as independent sitting.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics table
| Characteristic | Triac, n = 46 |
|---|---|
| Age younger than 4 years, n (%) | “11 (24%)”View highlighted excerpt for this quote |
| Age 4 to 10 years, n (%) | “19 (41%)”View highlighted excerpt for this quote |
| Age 11 to 18 years, n (%) | “11 (24%)”View highlighted excerpt for this quote |
| Adults older than 18 years, n (%) | “5 (11%)”View highlighted excerpt for this quote |
| Male, n (%) | “46 (100%)”View highlighted excerpt for this quote |
| White race, n (%) | “44 (96%)”View highlighted excerpt for this quote |
| No or poor head control, n (%) | “32 (70%)”View highlighted excerpt for this quote |
| Able to sit independently, n (%) | “5 (11%)”View highlighted excerpt for this quote |
| Uses a feeding tube, n (%) | “20 (43%)”View highlighted excerpt for this quote |
| Resting tachycardia (above the 90th percentile for age) | “19 (43%) of 44 patients with data available”View highlighted excerpt for this quote |
| Systolic hypertension | “12 (34%) of 35 patients with baseline blood pressure measurements”View highlighted excerpt for this quote |
Efficacy results
Primary endpoint: serum T3 concentration at month 12
“In the 45 patients assessed for the primary endpoint, serum T3 concentrations had significantly decreased by month 12 (median 13·1 months [IQR 12·4–13·9]), with a mean decrease of 3·15 nmol/L (95% CI 2·68–3·62; p<0·0001; figure 1; table 2), equivalent to 61% (56–66) from baseline.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Co-primary endpoints: TSH, free and total T4, and reverse T3
“We also identified significant reductions in serum free T4 concentrations (mean decrease 6·1 pmol/L, 5·4–6·8; p<0·0001) and serum TSH concentrations (mean decrease 1·89 mU/L, 1·39–2·39; p<0·0001). Additionally, serum total T4 concentrations decreased by 31·6 nmol/L (28·0–35·2; p<0·0001) and reverse T3 by 0·08 nmol/L (0·05–0·10; p<0·0001; (appendix p 7).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Primary and secondary outcomes, baseline to month 12
Attainment of the serum T3 target range
“In the post-hoc analyses to assess only the patients who completed 12 months of treatment, we found that 34 (85%) of 40 patients had attained serum T3 concentrations within the target range by month 12, and the remaining patients had concentrations just above the target range, but that their T3 measurements had been within the target range during the previous study assessment visit.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“By month 4, 35 (78%) of 45 patients had attained T3 concentrations within the target range (appendix p 6).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Secondary endpoints: bodyweight, heart rate, blood pressure, and tissue markers
“We assessed the secondary endpoints in the 40 patients who completed the 12-month treatment. We identified a significant increase in weight-for-age Z score at month 12 (0·27 SDs, 95% CI 0·03–0·50; p=0·0253; figure 1; table 2; appendix p 8), equating to a mean increase in body weight of 2·7 kg (1·9–3·5; p<0·0001); by contrast, in untreated patients, the bodyweight-for-age Z score has been shown to progressively reduce over time (appendix p 8).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between baseline and month 12, resting heart rate, as measured by electrocardiography, decreased by 9 bpm (95% CI 2–16; p=0·010), and mean heart rate, as measured by 24-h cardiac monitoring, decreased by 5 bpm (1–9; p=0·012; appendix p 9). Mean systolic blood pressure decreased over the 12-month study from the 78th percentile to the 61th percentile, equating to a change of 18 percentile points (95% CI 6–29; p=0·0037; table 2). The proportion of patients with systolic hypertension decreased from 34% (n=12/35) at baseline to 9% (n=3/32 at month 12).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The serum concentrations of sex hormone-binding globulin decreased by 35 nmol/L (15–55; p=0·0013). However, mean serum total cholesterol concentration did not significantly change between baseline and month 12 (difference 0·2, 95% CI 0·0–0·3; p=0·056). Finally, serum creatine kinase concentrations increased by 53 U/L (27–78; p<0·0001) by month 12 (table 2; appendix p 10).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Exploratory endpoint: gross motor function
“The greatest increase in gross motor function was in patients in whom Triac treatment was started before age 4 years (figure 1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“From the seven patients with a completely inactivating mutation who had started with Triac treatment before the age of 4 years, two reached this developmental stage by month 12 of treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Post-hoc treatment extension period
“Post-hoc analyses of the treatment extension endpoints included ten patients. During the long-term treatment extension period, the reductions in T3 concentrations persisted in all patients (figure 2; appendix p 21) and reductions in TSH and free T4 concentrations were maintained (appendix pp 11,21).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The improvement in bodyweight-for-age Z score was maintained, with a mean increase of 0·52 SDs (95% CI 0·02–1·02) at month 12 and 0·62 (0·12–1·12) at month 32, relative to baseline. Bodyweight (figure 2), height, and BMI trajectories improved relative to their anticipated natural course in seven (88%) of the eight paediatric patients (appendix p 12).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prescribing information: Study 2 serum total T3, baseline to month 12
| Variable | N | Baseline, mean (SD) | Month 12, mean (SD) | Difference, mean [95% CI] |
|---|---|---|---|---|
| T3, ng/dL | “45” | “323.4 (100.8)” | “118.3 (44.6)” | “-205.2 [-235.7; -174.6]” |
Prescribing information: Study 2 secondary endpoints at month 12
German benefit assessment: anthropometric results against a healthy reference population
Regulatory assessment of neurodevelopmental delay
Health-related quality of life and patient-reported outcomes
Prospectively collected quality-of-life and neurocognitive endpoints
Caregiver-reported outcomes from Triac Trial I: results
Safety results
Adverse events and treatment-related adverse events
“All 46 patients who received at least one dose of Triac were included in drug safety analyses. 43 (93%) patients had at least one adverse event (table 3; appendix p 22). Triac treatment was continued during hospital admission in all but one patient. All seven adverse events that were suspected to be related to Triac treatment, which occurred in six (13%) patients, were mild: three patients had a transient increase in perspiration and three patients reported transient irritability. The onset of these events coincided with the start of Triac treatment or modification in Triac dose and resolved spontaneously after a few days. No patients required a dose reduction or discontinued participation because of drug-related toxicity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Serious adverse events and death
“26 serious adverse events that were considered unrelated to treatment occurred in 18 (39%) patients (mostly hospital admissions because of infections).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most serious adverse events were intermittent infections that were treated with antibiotics and supportive care. All serious adverse events were considered to be secondary to MCT8 deficiency and, thus, unrelated to Triac (table 3). In three patients with preexisting seizures, an increase in seizure frequency was reported.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One patient died from pulmonary sepsis leading to multiorgan failure; post-mortem examination confirmed the clinical diagnosis, and other causes were excluded.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events in more than 10% of participants, serious events, and severity
Cardiac, bone, and liver safety measures
“Of the safety measures prespecified in the protocol (appendix p 14–16), no clinically relevant changes in cardiac structure or function were identified.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Serum β-carboxy-terminal collagen crosslinks increased by 0·14 µg/L (95% CI 0·03–0·25) and bone-specific alkaline phosphatase concentrations increased by 8·4 µg/L (2·7–14·1), without affecting bone mineral density (appendix p 23), consistent with the physiological increase of bone turnover markers in paediatric patients during development.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“25 (54%) of 46 patients showed mildly increased serum concentrations of alanine aminotransferase, aspartate aminotransferase, or γ-glutamyl transferase at baseline, which was attributed to the concomitant use of hepatotoxic medications, and these concentrations did not increase further during the study. Two (4%) patients showed an increase in aminotransferase concentrations that were attributed to commencement or dose adjustment of anticonvulsant drugs with known hepatotoxicity (levetiracetam and lamotrigine).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prescribing information: Study 2 transient increases in heart rate and systolic blood pressure during titration
German benefit assessment: adverse event reporting
Study limitations
Summary
Triac Trial I was an open-label, single-arm, phase 2 trial in which 46 participants were enrolled, 45 were included in the primary analysis, and 40 completed 12 months of treatment. The investigators state that the absence of a control group and the open-label design do not allow causality to be proven, that the sample size did not allow control for factors other than the intervention, that few adults were enrolled, and that missing measurements and withdrawals may have caused selection bias. The trial was not designed to assess neurodevelopment. The G-BA did not identify validated evidence linking a given change in serum T3 to individual symptoms, found no significant change in bodyweight or height z-scores against a WHO reference population, did not use the neurocognitive endpoints because fewer than 70% of assessments were returned, noted that no quality-of-life endpoints were collected, and could not rule out under-assessment of severe adverse events. The caregiver-reported outcomes come from a post-hoc analysis of an open-label trial.
Limitations stated by the investigators
“Inherent to studies in such a heterogeneous population, the effect size of outcomes varied within the study cohort, suggesting inter-individual variation in degree of benefit between patients. The small sample size did not allow identification or statistical control for factors other than the intervention that might modulate treatment effects. Another limitation was the small number of adult patients enrolled in the study, as a consequence of high mortality during childhood. Moreover, the low physical and cognitive abilities of the participants, a feature that is inherent to the disorder, precluded recording some study parameters in all patients. Together with study withdrawals, this issue might have, unavoidably, caused selection bias in the data used for statistical analyses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although our study design, including the absence of a control group and open-label design, does not enable us to prove causality, the observed unidirectional changes in serum T3 concentrations can likely be attributed to Triac treatment, given the substantial evidence from preclinical and clinical studies on the effects of Triac” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Our trial was not designed to detect whether Triac also modulates neurodevelopment in human MCT8 deficiency, since the study did not include specific neurodevelopmental outcomes and enrolled patients of all ages. Therefore, most patients studied would have passed the small window of opportunity to modulate brain development.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
German benefit assessment: absence of a comparator
ReTRIACt
Objective
Objective: effect of withdrawal on serum total T3
Location and study date
Study closure after the pre-NDA meeting
Study design
Phase and randomization ratio
Prescribing information: three study periods
Eligibility criteria
Age, sex, and stable maintenance treatment
Prescribing information: stable dose criterion for randomization
Treatment
Prescribing information: screening-period titration
Prescribing information: randomized treatment and follow-up periods
Study outcomes
Rationale for using serum t3 rate of change as the primary endpoint
Addition of the T3 rate-of-change endpoint after FDA comments
Sponsor rationale: serum T3 as the biochemical driver of disease
Prescribing information: primary efficacy endpoints and rescue criterion
Statistical analysis description
Number of participants (Planned and analyzed)
Prescribing information: randomized population
Description of analysis sets
Multiplicity control and handling of a discontinuation
Prescribing information: analysis set and model
| Analysis element | Quoted record |
|---|---|
| Analysis set for both primary endpoints | “Full Analysis Set” |
| Model for primary endpoint 1 | “Estimates from random effects model” |
Results
Participant disposition
Prescribing information: enrollment, randomization, and follow-up
Discontinuation during the randomized treatment period
Baseline characteristics
Prescribing information: age, sex, and race of enrolled participants
Prescribing information: baseline serum total T3 by arm
Efficacy results
Prescribing information: primary endpoint 1, total T3 rate of change
| Measure | Placebo | Tiratricol |
|---|---|---|
| N | “8” | “7” |
| T3 rate of change [95% CI] | “1.6 [1.2; 2.1]” | “1.1 [0.8; 1.3]” |
| Comparison | Value |
|---|---|
| Ratio of T3 rate of change, placebo/tiratricol [95% CI] | “1.5 [1.0; 2.2] (p-value=0.034)” |
Prescribing information: primary endpoint 2, rescue criterion
| Outcome | Tiratricol, N=7 | Placebo, N=8 |
|---|---|---|
| Rescue criterion not met, n (%) | “6 (85.7)” | “4 (50.0)” |
| Rescue criterion met, n (%) | “1* (14.3)” | “4 (50.0)” |
| Comparison | Value |
|---|---|
| Difference in proportions, placebo minus tiratricol | “0.36” |
| 95% CI | “-0.16, 0.77” |
Prescribing information: secondary heart rate and blood pressure endpoints
Primary endpoints in SI units, observed-case rescue analysis, and reinitiation
Congress report: estimated relative change in serum T3 over 30 days
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Serious adverse events and death
Study limitations
Summary
ReTRIACt enrolled 20 participants and randomized 15 of them (eight to placebo withdrawal, seven to continued tiratricol); in 2024 the manufacturer described the planned study as including 16 evaluable participants. The study was closed at the FDA's recommendation, and the analysis plan was revised to add the T3 rate-of-change endpoint (primary endpoint 1) before that endpoint was reported. Primary endpoint 1 met its significance criterion (ratio 1.5, 95% CI 1.0 to 2.2; p=0.034). For the rescue endpoint (primary endpoint 2), the difference in proportions was 0.36 with a 95% CI of -0.16 to 0.77 (p=0.182); one discontinuation in the tiratricol group for non-medical family reasons was counted as rescue, and the observed-case comparison was 4 versus 0 (p=0.070). The randomized period lasted at most 30 days and evaluated withdrawal after stable maintenance treatment; it did not evaluate treatment initiation or long-term clinical outcomes. The prescribing information reports adverse reactions for all 20 enrolled participants and does not report them by randomized arm. The congress report lists six serious adverse events in four participants and one death from aspiration pneumonia, none considered treatment-related. Enrolled participants were aged 5 to 31 years, so the study did not include infants.
Triac trial II
Objective
Principal investigator: early-treatment hypothesis
Location and study date
Registry dates and enrollment
| Field | Quoted record |
|---|---|
| Study start (actual) | “2020-12-07” |
| Primary completion (estimated) | “2027-07-18” |
| Study completion (estimated) | “2027-08-18” |
| Recruitment status | “Active, not recruiting” |
Registry study sites
Study design
Phase 2, open-label, multicentre, single-arm trial
| Design field | Quoted record |
|---|---|
| Phase | “Phase 2” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
Part I and long-term extension (Part II)
Eligibility criteria
Registry exclusion criteria
Treatment
Dose titration and target serum T3 range
Treatment duration and exposure
Study outcomes
Rationale for using GMFM-88 total score as a co-primary endpoint
Co-primary and secondary endpoints
Registry description of the GMFM-88 and BSID-III co-primary measures
Statistical analysis description
Number of participants (Planned and analyzed)
Enrolled and analyzed population
| Population | Quoted record |
|---|---|
| Enrollment (actual) | “22” |
Description of analysis sets
Historical control comparison and post-hoc analyses
Pre-specified historical control thresholds
Results
Participant disposition
Screening, exclusion, discontinuation, and completion
Baseline characteristics
Age, disease severity, and time since diagnosis
Nutritional status, feeding, heart rate, and blood pressure
Efficacy results
Co-primary endpoints versus historical controls
| Co-primary endpoint | Mean difference versus untreated historical cohort after 96 weeks |
|---|---|
| GMFM-88 total score | “-2.42, 95%CI -4.36 to -0.48” |
| BSID-III gross motor domain | “0.21, 90%CI -0.19 to 0.61” |
Co-primary endpoints: change from baseline
Sponsor topline report
Secondary endpoints: serum T3, body weight, blood pressure, and atrial ectopy
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Overview of treatment-emergent adverse events in Part I
| Event category | Participants, N=22, n (%) | Events |
|---|---|---|
| Any treatment-emergent adverse event (TEAE) | “21 (95.5)” | “208” |
| Any TEAE at least possibly related to study treatment | “13 (59.1)” | “20” |
| Any TEAE leading to discontinuation of study treatment | “0” | “0” |
| Any TEAE of CTC Grade 3 or higher | “13 (59.1)” | “19” |
| Any serious treatment-emergent adverse event (SAE) | “10 (45.5)” | “26” |
| Any SAE at least possibly related to study treatment | “1 (4.5)” | “2” |
| Any SAE leading to death | “0” | “0” |
Treatment-related adverse events and serious adverse events
Heart rate and bone markers at the higher dose
Congress and sponsor reports of tolerability
Study limitations
Summary
Triac Trial II was a single-arm, open-label phase 2 trial that enrolled 22 participants aged 5 to 28 months (median 16 months), of whom 21 completed 96 weeks. Neurodevelopmental outcomes were compared with historical scores from untreated participants in Triac Trial I; the co-primary endpoints were not met (GMFM-88 mean difference -2.42; BSID-III gross motor mean difference 0.21). The absence of a concurrent control group limits the separation of treatment effect from expected development, and the post-hoc improvements in other domains were not pre-specified. Only two participants were younger than 6 months at baseline. The trial targeted serum T3 at or below the lower limit of normal with a mean dose of 175 mcg/kg, compared with 37 mcg/kg in Triac Trial I; the EMA assessment reported increases in systolic blood pressure and markers of bone loss at these doses, and the G-BA excluded the trial from the German benefit assessment because its titration targets differed from the product information. Serious adverse events occurred in 10 of 22 participants (45.5%). The results summarized here come from a regulatory assessment, a manufacturer topline report, a registry record, and a 2026 congress abstract.
Regulatory appraisal: uncontrolled design, timing, and dose
German benefit assessment: dosing outside the product information
EMC cohort study
Objective
Stated objective of the cohort study
“Our previous trial showed improvement of key clinical and biochemical features during 1-year treatment with the T3 analogue Triac, but long-term follow-up data are needed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Also, it is relevant to determine whether the efficacy of a treatment demonstrated in a clinical trial (typically with a limited number of patients intrinsic to the low prevalence) is applicable in a real-life setting. Such long-term follow-up data of patients with MCT8 deficiency treated with Triac are currently lacking, particularly in young patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a joint international effort, we here retrospectively report long-term (up to 6 years) real-life follow-up data on children and adults with MCT8 deficiency treated with Triac.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Study sites and observation dates
“Between October 15, 2014, and January 1, 2020, 67 patients from 62 different families (with 46 different MCT8 mutations) had received Triac and were eligible for inclusion in this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were treated in 33 different sites in 18 countries: 19 sites were located in Europe, 4 in the Americas, 5 in Asia, 4 in Oceania and 1 in Africa (Supplementary Figure 2 (12)).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Follow-up of the remaining patients continued to January 1, 2021.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study design
Retrospective real-life cohort of off-label treatment
“In this international pragmatic real-life cohort, data were collected retrospectively in patients with MCT8 deficiency, within our consortium of 33 hospitals in 18 countries, who have been treated with the T3 analogue Triac on an off-label use basis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The cohort consisted of (1) patients who finished the Triac Trial I protocol and continued on Triac treatment on an off-label use basis; and (2) additional patients who were identified after the recruitment phase of Triac Trial I or could not be enrolled in the Triac Trial I due to the absence of study sites in their country. For patients who had been enrolled in the Triac Trial I, data from the assessments at baseline and after 1 year of Triac treatment have been re-utilized and extended by novel long-term follow-up data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Consent and ethics review
“The parents or guardians of all patients provided consent for off-label use of Triac to their caregiving physician. Under off-label use and with retrospective collection of data that are part of routine clinical care from medical files, no institutional board approval was needed in the majority (30) of hub centers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Inclusion criteria
“Eligible subjects were those with MCT8 deficiency (confirmed by the presence of a pathogenic mutation in the SLC16A2 gene), irrespective of age or comorbidities, who were treated with Triac on an off-label use basis following our previously established dose escalation protocol (11), and had their biochemical parameters measured in the central laboratory of the Erasmus MC, The Netherlands. This approach allowed for a uniform strategy of Triac dosing and monitoring of effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Washout, starting dose, and dose escalation
“All patients discontinued antithyroid drugs, levothyroxine, or other thyroid hormone analogs (if applicable, eg, diiodothyropropionic acid [DITPA]) before treatment with Triac was initiated. After a washout period of 2 weeks, baseline measurements were recorded.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The daily starting dose was based on body weight (175 µg Triac < 10 kg; 350 µg Triac ≥ 10 kg). The daily dose was increased with increments of 175 µg or 350 µg with a goal of attaining serum total T3 concentrations within the target range of 1.4 to 2.5 nmol/L. Guided by the exploratory neurodevelopmental outcomes in Triac Trial I (11), serum T3 concentrations < 1.4 nmol/L were allowed in children under 2.5 years of age in the absence of dose-limiting toxicities, leaving the possibility to administer higher Triac dosages, possibly increasing the potential for neurocognitive benefits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Time to maintenance dose and maintenance dose
“The mean time to reach the maintenance dose was 5.0 (SD 4.7) months, with a mean of 2.7 (SD 1.1) dose increments. The median maintenance dose was 38 µg/kg/day (interquartile range, 31-61 µg/kg/day; range, 15-105 µg/kg/day).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment duration and exposure
“The median treatment duration was 2.2 years (range, 0.2-6.2 years). Twelve (18%) of the 67 patients were treated for a period of more than 5 years and 26 (39%) of 67 patients were treated for a period of 2 to 5 years. The treatment exposure in this cohort was 180.4 patient years (Supplementary Figure 3B (12)).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using serum t3 concentration as the primary endpoint
Primary and secondary endpoints
“The primary prespecified endpoint of this study was the change in serum T3 concentrations between baseline and last available measurement. The prespecified secondary endpoints were the change between baseline and last available body weight and body height (expressed as kg and cm, or weight-for-age and weight-for-height and height-for-age Z-scores, respectively, or as relative differences to the natural history reference; see Supplementary Methods (12)); heart rate (expressed as beats per minute, or heart-rate-for-age Z-score); serum thyroid-stimulating hormone (TSH; thyrotropin), free and total T4 concentrations; established biochemical markers that reflect thyroid hormone action in the liver (sex hormone-binding globulin [SHBG]), in the kidney (creatinine) and in muscle (creatine kinase [CK]); and Tanner stage of sexual maturation in patients who were aged between 8 and 18 years during treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The occurrence of (severe) adverse events related to Triac was actively monitored during treatment (see Supplementary Methods (12)).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale stated by the investigators: peripheral thyrotoxicosis
“In MCT8-independent tissues, the elevated serum T3 concentrations cause chronic thyrotoxicosis with negative clinical sequelae that include being underweight and having cardiovascular dysfunction (8). Together, these disease characteristics result in substantial morbidity throughout life and predispose to high mortality in childhood (8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
German benefit assessment: clinical relevance of serum T3
Statistical analysis description
Number of participants (Planned and analyzed)
Analysis populations
“All 67 participants received Triac and had at least 1 follow-up measurement of serum T3 concentrations and thus were included in the analysis of the primary endpoint. Of these 67 patients, 4 patients had not been treated longer than the mean time to optimal dose (5.0 months) and thus 63 participants were included in the analyses of the secondary endpoints. Of these 63 patients, 12 (19%) patients were treated for ≥ 5 years, 10 (16%) patients were treated for 3 to 5 years, 34 (53%) patients were treated for 1 to 3 years, and 7 (13%) patients were treated for < 1 year. Longitudinal within-subject analyses were performed in 38 patients with at least 2 years of follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Full analysis set and secondary-outcome set
“Analysis on the primary outcome was based on the full analysis dataset, which included all patients who received at least 1 dose of Triac and who had at least 1 follow-up visit after the baseline assessment. Analyses on all prespecified secondary outcomes were done in all subjects who had a treatment duration that exceeded the mean time of dose escalation (defined as time from baseline measurement to the first follow-up visit on optimal dose), to ensure that treatment effects on secondary outcomes could be reliably assessed. Complementary analyses of secondary outcomes were performed on the full analysis dataset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical methods
“For all endpoints, P values and 95% CIs were calculated for the mean change between baseline and last available follow-up visit using paired t tests. Serum TSH and CK concentrations were first log-transformed to normalize the distribution. Complementary analyses after stratification by treatment duration (< 1 year, from 1 to 3 years, from 3 to 5 years and ≥ 5 years) were done using 1-way analysis of variance (ANOVA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In longitudinal within-subject analyses of the primary and secondary endpoints, performed in all subjects who were treated for at least 2 years, baseline data were compared with those obtained after 1 year (±4 months) of treatment and at the last available follow-up visit within the same subject, using repeated-measurement ANOVA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Missing data
“Missing data can mainly be attributed to the poor clinical condition of patients (including restricted availability of serum); common manifestations of MCT8 deficiency, such as scoliosis and dystonic posturing that hamper investigations for which patients needed proper positioning; and patients receiving clinical care outside the designated hub centers. With the assumption that omission of data occurred randomly, and given the broad age range of the participants and small group size, pairwise deletion was used to adjust when the baseline data point was missing; for missing data that were captured throughout the treatment period, the last available measurement was used (if available).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Historical natural-history comparison for growth outcomes
“Deterioration of body weight and height with increasing age is part of the natural history of patients with MCT8 deficiency who are not treated with Triac (8). Therefore, the results of anthropometric parameters were expressed against the natural history of untreated patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Enrollment pathways and overlap with Triac Trial I
“Among them, 27 patients had been enrolled in Triac Trial I and continued Triac treatment on an off-label use basis after completion of the trial protocol. Another 40 patients had been identified after the recruitment phase of Triac Trial I (n = 28) or could not be enrolled in the Triac Trial I due to the absence of study sites in their country (n = 12) (Supplementary Figure 1 (12)).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Deaths and discontinuations during follow-up
“During the study period, 3 patients died and 10 other patients discontinued Triac therapy (in 4 cases the parents decided to discontinue due to a lack of perceived benefit; 2 patients discontinued due to financial constraints or unavailability of Triac, and 4 patients discontinued for unknown reasons).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Baseline age
“At baseline, the median age was 4.6 years, with a range of 0.5 to 66 years. Of the 67 patients, 63 (94%) were younger than 18 years of age and 23 (34%) were younger than 2.5 years (Table 1 and Supplementary Figure 3A (12)).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline cohort characteristics
“Body weight-for-age data were available for 66 patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Heart rate data were available for 60 patients (denominator for percentage calculation).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Primary endpoint: serum T3 concentration at the last available visit
“In the 67 patients assessed for the primary endpoint, mean serum T3 concentration decreased from 4.58 (SD 1.11) to 1.66 (SD 0.69) nmol/L (mean difference 2.92 nmol/L; 95% CI, 2.61-3.23 nmol/L; P < 0.0001; Fig. 1A and Table 2). Sixty (90%) of 67 patients reached T3 concentrations below 2.5 nmol/L, the upper limit of the target range.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients who were treated for more than 2 years, serum T3 concentrations after 1 year of treatment and at the last visit did not significantly differ but were significantly reduced compared with baseline, indicating a sustained treatment effect (Fig. 1D and Supplementary Table 2 (12)).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Changes from baseline to last visit in predefined outcomes
Body weight relative to the healthy reference population and to untreated historical controls
“In the 63 patients analyzed for secondary endpoints, the mean body-weight-for-age Z-score increased, but not statistically significantly, from −2.81 SD (SD 1.94) at baseline to −2.64 SD (SD 1.81) at the last visit (mean difference 0.17 SD; 95% CI, −0.18 to 0.53; P = 0.3263), representing a mean increase of 5.7 kg (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean body weight-for-age Z-score at baseline was 0.07 SD-points above the natural history reference line and at last visit 0.79 SD-points above the natural history reference line, corresponding to a statistically significant mean increase of 0.72 SD-points (95% CI, 0.36-1.09; P = 0.0002, Table 2). Compared with the natural history of treatment-naïve patients with MCT8 deficiency, body weight-for-age improved (> 0.25 SD increase compared with the natural history reference) in 32 (57%) of 55 patients upon treatment and remained stable (−0.25 to 0.25 SD change compared with the natural history reference) in 11 (20%) of 55 patients (Fig. 1E).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Body height
“The mean body height-for-age increased from baseline to last visit by a mean of 15 cm, although the body height-for-age score did not significantly differ between baseline and last visit (mean difference −0.09 SD, 95% CI, −0.5 to 0.32; P = 0.6705) (Table 2). The mean body height-for-age Z-score at baseline was 0.44 SD-points under the natural history reference line and at last visit 0.14 SD-points above the natural history reference line, corresponding with a mean increase of 0.58 SD-points (95% CI, 0.12-1.05; P = 0.0139, Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Heart rate
“Mean heart-rate-for-age Z-score decreased significantly (mean difference −0.64 SD; 95% CI, −0.98 to −0.29; P = 0.0005; Fig. 1G and Table 2), improving (> 0.25 SD decrease) in 29 (60%) of 48 patients and remaining stable (−0.25 to 0.25 SD change) in 10 (21%) of 48 patients. The proportion of patients with tachycardia (heart rate above the 90th percentile for the corresponding age, with cutoffs described by Fleming and colleagues (13)) decreased from 18 (38%) of 48 patients at baseline to 11 (23%) of 48 patients at the last visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Thyroid function and tissue markers of thyroid hormone action
“Mean serum TSH, free T4, and total T4 concentrations significantly declined upon Triac treatment (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean SHBG concentration, reflecting the liver-specific status of thyroid hormone action, decreased from 245 (SD 99) to 209 (SD 92) nmol/L (mean difference 36 nmol/L; 95% CI, 16-57; P = 0.0008) (Fig. 2A and Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Creatinine, reflecting renal thyroid hormone activity, increased from 32 (SD 11) to 39 (SD 13) µmol/L (mean difference 7 µmol/L; 95% CI, 6-9; P < 0.0001) (Fig. 2C and Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, CK, a marker of thyroid hormone activity in skeletal muscle, showed no statistically significant changes on Triac treatment [110 (SD 87) to 128 (SD 80) U/L; mean increase 18 U/L; 95% CI, −8 to 45; P = 0.2166; Fig. 2E and 2F and Table 2].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sexual maturation
“Available Tanner stage at the last visit of patients aged from 8 to 18 years during treatment showed delayed sexual maturation in 5 (29%) out of 17 patients (Supplementary Figure 7 (12)), similar to untreated patients with MCT8 deficiency (8). No effects of Triac treatment on sexual maturation were reported in these patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Adverse events and hospitalizations related to tiratricol
“No severe adverse events related to Triac were reported during follow-up. Transient signs of increased thyrotoxicosis (increased irritability and anxiety, reduced sleep, increase in blood pressure, and tachycardia) were reported in a small subset of patients (5 of 67 patients; Supplementary Table 4). No hospitalizations related to Triac were reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Deaths during follow-up
“During the total treatment period, 3 patients died: a 13-year-old patient died due to sudden death, a 71-year-old patient died after aspiration and a 14-year-old patient died of unknown cause. This is in line with commonly observed causes of death in MCT8 deficiency, with cause of death also often being unknown (8). Postmortem examination was performed in none of the cases. At the time of death, all patients had been on a stable dose of Triac for > 1.5 years, > 4 years, and >2.5 years, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary
This retrospective cohort included 67 participants treated off-label at 33 sites, of whom 27 (40%) had completed Triac Trial I; the baseline and 1-year data of those 27 participants are counted in both studies. Treatment duration ranged from 0.2 to 6.2 years, 4 participants were excluded from the secondary-outcome analyses, and missing measurements were handled by pairwise deletion and last available measurement. The change in body-weight-for-age Z-score relative to the healthy reference population was 0.17 SD (P = 0.3263), and the 0.72 SD increase was measured against a historical natural-history reference. The investigators state that the cohort may not represent all patients with MCT8 deficiency, that the real-life setting impeded optimal collection of efficacy and safety data, that care outside the designated centers could hamper adverse event reporting, and that neurodevelopmental outcomes were not collected uniformly. No concurrent comparator was included.
Limitations stated by the investigators
“This study has several limitations. First, it is unknown whether this cohort is fully representative for the entire population of patients with MCT8 deficiency. This cohort, however, represents a significant proportion of known patients (67 patients out of approximately 225 patients known in literature (8)). Second, this observational study collecting data on off-label use of Triac treatment in patients with MCT8 deficiency in a real-life treatment setting provides a less-controlled environment compared with a clinical trial, impeding optimal collection of efficacy and safety data. Patients have potentially also received care outside of their designated center, which could hamper reporting of adverse events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Third, this study precludes determining the optimal Triac dose for MCT8 deficiency for both the peripheral and neurocognitive phenotype as data on neurodevelopmental outcomes had not been uniformly collected.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EMC survival study
Objective
Survival objective
Location and study date
International data collection
Study design
Sponsor analysis of the Erasmus University Medical Center cohort
Eligibility criteria
Exclusion criteria and mutation classification
Treatment
No evidence found.
Study outcomes
Rationale for using all-cause mortality as the primary endpoint
Mortality in MCT8 deficiency and the link to thyrotoxicosis
Statistical analysis description
Number of participants (Planned and analyzed)
Screened and included populations in the congress analysis
Study size reported in the New Drug Application
Description of analysis sets
Baseline comparisons, missing data, and survival models
Results
Participant disposition
Screening, exclusion, and follow-up
Baseline characteristics
Efficacy results
All-cause mortality: congress analysis
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
The congress analysis included 228 of 484 screened participants and compared 111 treated participants with 117 untreated participants; it reported 5 versus 27 deaths over a median follow-up of 4.8 years after diagnosis. Treatment was not randomized, and the treated and untreated groups differed in the proportion residing in Western countries (78% versus 57%). The reported hazard ratio (0.28, 95% CI 0.09 to 0.91) is an observational association; the authors state that confounding and immortal time bias remain potential threats to validity and that further analyses were ongoing. Missing data were handled by multiple imputation. Later manufacturer documents describe the EMC Survival Study as including more than 600 participants, while the only quoted estimate comes from the 228-participant congress analysis. As of the second-quarter 2026 interim report, the survival data had not yet been published in a peer-reviewed journal.
Pediatric TRIAC case series
Objective
Location and study date
Institution and enrollment period
| Characteristic | Value |
|---|---|
| Institution | “Hospital de Pediatría S.A.M.I.C. Prof. Dr. Juan P. Garrahan, City of Buenos Aires, Argentina” |
Study design
Single-center case series
Eligibility criteria
Treatment
Treatment start date and current daily dose by participant
| Participant | Start date | Current dose |
|---|---|---|
| Participant 1 | “Nov-2019” | “22 μg/kg” |
| Participant 2 | “Jun-2020” | “18 μg/kg” |
| Participant 3 | “Jan-2022” | “10 μg/kg” |
| Participant 4 | “Jun-2022” | “26 μg/kg” |
Study outcomes
Rationale for using serum t3 concentration as a biochemical outcome
Elevated T3 as the biochemical marker of MCT8 deficiency
Thyroid hormone assays
Statistical analysis description
Number of participants (Planned and analyzed)
Included participants
| Population | Participants |
|---|---|
| Children treated with tiratricol | “4” |
Description of analysis sets
No evidence found.
Results
Participant disposition
Follow-up and treatment duration by participant
| Participant | Follow-up duration | Treatment duration |
|---|---|---|
| Participant 1 | “3 years and 6 months” | “32 months” |
| Participant 2 | “2 years and 6 months” | “22 months” |
| Participant 3 | “1 year and 1 month” | “6 months” |
| Participant 4 | “7 months” | “5 months” |
Baseline characteristics
Age, sex, and clinical presentation at diagnosis
Thyroid function at diagnosis
Efficacy results
Biochemical response
Total T3 at diagnosis and at the last control by participant
| Participant | Total T3 at diagnosis, ng/mL | Total T3 at last control, ng/mL |
|---|---|---|
| Participant 1 | “3.3 (NV: 0.29–2.26)” | “2.7 (NV: 0.29–2.26)” |
| Participant 2 | “3.19 (NV: 1.03–2.3)” | “2.12 (NV: 1.03–2.3)” |
| Participant 3 | “4.7 (NV: 0.99–2.14)” | “1.52 (NV: 0.99–2.14)” |
| Participant 4 | “3.56 (NV: 0.29–2.26)” | “2.08 (NV: 0.29–2.26)” |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
The series included four participants from a single hospital and did not include a concurrent control group. Treatment duration ranged from 5 to 32 months. The authors describe retrospective data collection and unequal access to developmental stimulation therapies. The observed biochemical response and absence of reported adverse reactions in four participants cannot establish comparative effectiveness, quantify uncommon harms, or separate treatment effects on development from concomitant supportive care.
Limitations stated by the authors
Early TRIAC intervention case report
Objective
Location and study date
Institution
| Characteristic | Value |
|---|---|
| Institution | “Şanlıurfa Training and Research Hospital, Clinic of Pediatric Endocrinology, Şanlıurfa, Turkey” |
Study design
Eligibility criteria
Referral and genetic diagnosis
Treatment
Treatment initiation and dose titration
Study outcomes
Rationale for using BSID-III composite scores as a neurodevelopmental outcome
Gap in neurodevelopmental evidence
Neurodevelopmental assessment method
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Not applicable.
Results
Participant disposition
Follow-up and adherence
Baseline characteristics
Clinical and biochemical findings at referral to endocrinology (19 months)
Neurodevelopmental status before treatment
Efficacy results
Neurodevelopmental outcomes at 6 and 12 months
Peripheral thyrotoxicosis outcomes
Clinical and biochemical measures at baseline and after 12 months of treatment
| Measure | Baseline (21 months of age) | 12 months after treatment start |
|---|---|---|
| Weight SDS | “-2.9” | “-1.8” |
| Resting heart rate, bpm (percentile) | “150 (90th-99th)” | “95 (25th)” |
| TSH, mIU/mL | “0.8” | “0.7” |
| Free T3, pmol/L | “11.7” | “7.5” |
Free T3 immunoassay interference during treatment
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Drug-related adverse effects
Study limitations
Summary
This is one participant followed without a comparator. BSID-III composite scores remained below two SDS for age at 6 and 12 months despite attainment of individual developmental milestones. The report also describes adherence interruptions of 3 to 4 consecutive days, suspected free T3 immunoassay interference, and oral baclofen introduced at 6 months. These factors limit attribution of changes to tiratricol. The maintenance dose (1,500 mcg/day, 133 mcg/kg/day) was higher than doses previously described, and a single participant provides no estimate of adverse-event frequency.
Limitations stated by the authors
Real-world tiratricol case report
Objective
Location and study date
Institutions
Study design
Eligibility criteria
Clinical course and genetic diagnosis
Treatment
Tiratricol initiation and dose adjustment
Prior levothyroxine treatment
Study outcomes
Rationale for using clinical response as an outcome measure
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Not applicable.
Results
Participant disposition
No evidence found.
Baseline characteristics
Thyroid function before tiratricol (32 months of age)
| Measure | Value |
|---|---|
| TSH | “4,52 mU/l” |
| Free T4 | “6,61 pmol/l” |
| Free T3 | “14,72 pmol/l” |
Efficacy results
Clinical and biochemical course during treatment
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
The evidence for this case is one participant described in a congress abstract without a comparator. The abstract gives the starting dose in micrograms per day and later doses in mg/kg per day, so the dose units cannot be confirmed from the abstract. Epileptic encephalopathy and antiepileptic treatment during follow-up limit attribution of psychomotor changes to tiratricol. The full case report could not be retrieved for this review.
Bioavailability/Bioequivalence study
Objective
Primary and secondary objectives
Registered primary objective
Location and study date
Study site, sponsor, and enrollment dates
| Characteristic | Value |
|---|---|
| Study participating centre | “Quotient Sciences Limited” |
| Country of recruitment | “United Kingdom” |
| Sponsor | “Rare Thyroid Therapeutics International AB” |
| Protocol serial number | “Sponsor code MCT8-2023-5” |
| Date of first enrolment | “06/07/2023” |
| Date of final enrolment | “31/08/2023” |
Study design
Randomized five-period crossover design
Eligibility criteria
Key inclusion criteria
| Criterion | Registered text |
|---|---|
| Age | “Aged 18 to 55 years inclusive at the time of signing informed consent” |
| Sex and health status | “Healthy males” |
| Body mass index | “Body mass index (BMI) of 18.0 to 32.0 kg/m2 as measured at screening” |
| Body weight | “Weight 50 to 100 kg at screening” |
Selected exclusion criteria
Treatment
Registered treatments
Study outcomes
Rationale for using AUC and maximum serum concentration as the bioequivalence endpoints
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Safety and pharmacokinetic analysis counts by treatment
| Treatment | Safety analysis | Pharmacokinetic analysis |
|---|---|---|
| A: round tablet, 350 micrograms, fasted | “29” | “29” |
| B: oblong tablet, 350 micrograms, fasted | “29” | “28” |
| C: oblong tablet, 1,050 micrograms, fasted | “24” | “24” |
| D: oblong tablet, 1,050 micrograms, fed | “20” | “20” |
| E: oblong tablet, 175 micrograms, fasted | “25” | “25” |
| F: oblong tablet, 175 micrograms, fed | “20” | “20” |
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Food effect
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Tolerability and serious adverse events
Study limitations
Summary
This single-dose crossover study enrolled 30 healthy adult male participants aged 18 to 55 years. Its results address formulation comparability, food effects, and dose proportionality. Analysis counts ranged from 20 to 29 participants per treatment, and the congress abstract does not report participant disposition, baseline demographics, adverse-event counts, or confidence intervals for the bioequivalence comparison. The registry record states that participant-level data will not be shared. Single-dose exposure in adults provides limited information on safety during lifelong treatment in children.